J M Molina

Summary

Country: France

Publications

  1. ncbi Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
    J M Molina
    Clinique des Maladies Infectieuses, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Infect Dis 182:599-602. 2000
  2. ncbi Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients
    J M Molina
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    Antivir Ther 4:71-4. 1999
  3. ncbi Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA
    J M Molina
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    AIDS 14:1341-8. 2000
  4. ncbi The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
    J M Molina
    Clinique des Maladies Infectieuses, Hopital Saint Louis, 75475 Paris Cedex 10, France
    J Infect Dis 180:351-8. 1999
  5. ncbi Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial
    J M Molina
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 177:1373-7. 1998
  6. doi Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial
    M A Valantin
    Department of Clinical Infectious and Tropical Diseases, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:625-35. 2008
  7. ncbi Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study
    S Fournier
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique, Hopitaux de Paris, Paris, France
    HIV Med 6:129-34. 2005
  8. ncbi Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)
    J M Molina
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    HIV Med 5:99-104. 2004
  9. pmc Determination of types of Enterocytozoon bieneusi strains isolated from patients with intestinal microsporidiosis
    O Liguory
    Laboratory of Microbiology, Hopital Hotel Dieu, Paris, France
    J Clin Microbiol 36:1882-5. 1998
  10. ncbi Diagnosis of infections caused by Enterocytozoon bieneusi and Encephalitozoon intestinalis using polymerase chain reaction in stool specimens
    O Liguory
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    AIDS 11:723-6. 1997

Collaborators

Detail Information

Publications71

  1. ncbi Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
    J M Molina
    Clinique des Maladies Infectieuses, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    J Infect Dis 182:599-602. 2000
    ..The once-daily combination therapy of emtricitabine, didanosine, and efavirenz was safe and demonstrated strong antiviral and immunologic effects that lasted for the 24-week period of the study...
  2. ncbi Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients
    J M Molina
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    Antivir Ther 4:71-4. 1999
    ....
  3. ncbi Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. ANRS 054 Study Group. Agence Nationale de Recherche sur le SIDA
    J M Molina
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    AIDS 14:1341-8. 2000
    ..This study was designed to assess the safety and efficacy of oral fumagillin in this infection...
  4. ncbi The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
    J M Molina
    Clinique des Maladies Infectieuses, Hopital Saint Louis, 75475 Paris Cedex 10, France
    J Infect Dis 180:351-8. 1999
    ..The combination of stavudine plus didanosine reduced plasma HIV-1 RNA concentrations and increased CD4 cell counts more effectively than did the combination of zidovudine plus lamivudine or the regimen alternating both combinations...
  5. ncbi Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial
    J M Molina
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 177:1373-7. 1998
    ..04, one-sided log-rank test). In human immunodeficiency virus-infected patients with E. intestinalis infection, albendazole has parasitologic and clinical efficacy and reduces the risk of relapse...
  6. doi Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial
    M A Valantin
    Department of Clinical Infectious and Tropical Diseases, Pitie Salpetriere Hospital, Paris, France
    HIV Med 9:625-35. 2008
    ..To evaluate the impact on peripheral fat tissue of a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen in lipoatrophic HIV-1 infected patients...
  7. ncbi Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study
    S Fournier
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique, Hopitaux de Paris, Paris, France
    HIV Med 6:129-34. 2005
    ..To assess the antiviral response to optimized therapy following genotypic resistance testing and to identify factors associated with virological response in HIV-1-infected patients failing antiretroviral therapy...
  8. ncbi Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)
    J M Molina
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    HIV Med 5:99-104. 2004
    ..This study was conducted to investigate the pharmacokinetics of emtricitabine (FTC), didanosine (ddI), and efavirenz (EFV) when administered in a once-daily combination...
  9. pmc Determination of types of Enterocytozoon bieneusi strains isolated from patients with intestinal microsporidiosis
    O Liguory
    Laboratory of Microbiology, Hopital Hotel Dieu, Paris, France
    J Clin Microbiol 36:1882-5. 1998
    ..PCR-RFLP analysis of the ITS region of E. bieneusi should be useful for epidemiological studies...
  10. ncbi Diagnosis of infections caused by Enterocytozoon bieneusi and Encephalitozoon intestinalis using polymerase chain reaction in stool specimens
    O Liguory
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    AIDS 11:723-6. 1997
    ..To study the usefulness of polymerase chain reaction (PCR) for the species identification of microsporidia in stool specimens obtained from HIV-infected patients with Enterocytozoon bieneusi or Encephalitozoon intestinalis infections...
  11. ncbi Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy
    J M Molina
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 171:245-9. 1995
    ..In 2 patients, however, microsporidian spores were detected in feces during follow-up and mild diarrhea recurred. Therefore, albendazole seems to have a significant but transient effect in treatment of S. intestinalis infection...
  12. ncbi Detection and species identification of intestinal microsporidia by polymerase chain reaction in duodenal biopsies from human immunodeficiency virus-infected patients
    F David
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 174:874-7. 1996
    ..intestinalis. PCR testing of intestinal biopsy specimens can be used successfully for rapid detection and species differentiation of intestinal microsporidia and thus could be a valuable alternative to transmission electron microscopy...
  13. ncbi Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients
    L Hocqueloux
    Clinique des Maladies Infectieuses, Departement de Biostatistique et Informatique Medicale, Laboratoire de Biochimie B, Hopital Saint Louis, Paris, France
    HIV Med 4:18-23. 2003
    ..We describe the prevalence, risk factors and outcome of hyperlactataemia (HL) in a cohort of 140 HIV-infected patients...
  14. doi Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study
    Roland Landman
    Service des Maladies Infectieuses et Tropicales, AP HP, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    J Antimicrob Chemother 64:118-25. 2009
    ..We evaluate the efficacy and tolerability of ritonavir-boosted dual protease inhibitor as a nucleoside reverse transcriptase inhibitor-sparing regimen in a prospective open-label randomized pilot trial in antiretroviral-naive patients...
  15. ncbi HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV
    M Guiguet
    INSERM U720, Paris, France
    HIV Med 8:124-30. 2007
    ..To determine the incidence of Isospora belli infection in HIV-infected patients in France, and to study risk factors...
  16. ncbi Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
    V Picard
    Laboratory of Virology, , Paris, France
    J Infect Dis 184:781-4. 2001
    ....
  17. ncbi Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial
    Marie Anne Bouldouyre
    Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and University of Paris Diderot Paris 7, France
    J Acquir Immune Defic Syndr 52:531-7. 2009
    ..Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated...
  18. ncbi Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus
    A Boyd
    INSERM, Paris and UMR S707, Universite Pierre et Marie Curie PARIS6, Paris, France
    J Viral Hepat 17:65-76. 2010
    ..Peaks and rebounds from undetectable hepatitis B, C and/or D viremia warrant closer follow-up in this patient population. HDV-replication was uncontrolled even with antiviral treatment...
  19. doi Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France
    M Lagrange-Xelot
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    HIV Med 9:126-30. 2008
    ..Isosporiasis, a rare cause of diarrhoea among HIV-infected patients in the pre-highly active antiretroviral therapy (HAART) era, seems to be re-emerging...
  20. doi Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]
    M Lafaurie
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    HIV Med 14:410-20. 2013
    ..The aim of the study was to demonstrate the noninferiority of polyacrylamide hydrogel (PH) vs. polylactic acid (PLA) for the treatment of facial lipoatrophy in HIV-infected adults...
  21. pmc X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI
    Jade Ghosn
    Universite Paris Descartes, EA 3620, CHU Necker Enfants Malades, Paris, France
    PLoS ONE 6:e23301. 2011
    ..X4-tropic variants present at baseline were still exclusive (patients D and E) or dominant (at least one time point, patient C) far from PHI...
  22. ncbi Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features
    J M Molina
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 167:217-21. 1993
    ..001) than did patients without intestinal microsporidiosis. Intestinal microsporidiosis appears to be a frequent cause of unexplained chronic diarrhea in patients with AIDS and is associated with diminished D-xylose absorption...
  23. doi Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial
    Matthieu Lafaurie
    Department of Infectious Diseases, Saint Louis Hospital, University of Paris 7, INSERM U897, 1 avenue Claude Vellefaux 75010 Paris, France
    J Antimicrob Chemother 62:1122-9. 2008
    ..However, it is unclear whether patients tolerating long-term zidovudine-containing regimens will benefit from a switch to non-zidovudine-containing regimens...
  24. doi Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients
    Claudine Duvivier
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris, France
    AIDS 23:817-24. 2009
    ..To evaluate the change in bone mineral density (BMD) at specific sites in patients initiating antiretroviral therapy in a substudy of the ANRS 121 trial...
  25. pmc Evidence of different Enterocytozoon bieneusi genotypes in patients with and without human immunodeficiency virus infection
    O Liguory
    Departments of Infectious Diseases, , Paris, France
    J Clin Microbiol 39:2672-4. 2001
    ..bieneusi among these patients...
  26. ncbi High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia
    M Lafaurie
    Infectious Diseases Intervention Unit, Saint Louis Hospital, Paris, France
    Clin Microbiol Infect 16:1191-6. 2010
    ..1, p 0.32). The observed high rate of invasive aspergillosis among caspofungin recipients requires further evaluation...
  27. ncbi Risk factors for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study
    Y J Hutin
    Division of Infectious Diseases, Hopital Saint Louis, Paris, France
    J Infect Dis 178:904-7. 1998
    ....
  28. pmc Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
    J J Laurichesse
    Laboratoire de Recherche en Pathologie Infectieuse, Universite Paris 7, Paris, France
    HIV Med 11:239-44. 2010
    ..The aim of the study was to determine whether the chemokine (C-C motif) receptor 5 (CCR5) Delta32 deletion is associated with long-term response to combination antiretroviral treatment (cART) in HIV-1-infected patients...
  29. ncbi Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial
    V de Lastours
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France University Paris Diderot, Sorbonne Paris Cité, Paris, France
    HIV Med 15:23-9. 2014
    ..Epstein-Barr virus (EBV) replication is associated with an increased risk of lymphoma in immunocompromised patients. We assessed whether IL-2 had an impact on EBV replication and the development of lymphoma...
  30. doi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  31. doi Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens
    H L Nguyen
    Virology Department, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, INSERM U941, Paris Diderot University, Sorbonne Paris Cité, Paris, France
    HIV Med 14:85-91. 2013
    ....
  32. ncbi Multifocal Epstein-Barr virus-associated smooth muscle tumor in adults with AIDS: case report and review of the literature
    S Gallien
    Department of Infectious Disease, Saint Louis Hospital and University Paris 7, Paris, France
    Oncology 74:167-76. 2008
    ..The aim of this study was to provide a systematic review of Epstein-Barr virus-associated smooth muscle tumors (EBV-SMT) in human immunodeficiency virus (HIV)-infected adults, focusing on clinical and histopathologic features and outcome...
  33. ncbi Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens
    S Fournier
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    J Infect Dis 183:1586-91. 2001
    ..3-50.2) and anti-Toxoplasma IgG titer >150 IU/mL (OR, 5; 95% CI, 1.6-15.2). Immune reconstitution under highly active antiretroviral therapy was associated with a restoration of immune responses against Toxoplasma...
  34. ncbi [Metastatic cancer of the prostate in a 40-year-old HIV-infected male patient]
    A Furco
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
    Presse Med 32:644-5. 2003
    ..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature...
  35. doi Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007
    N De Castro
    Department of Infectious Diseases, AP HP Hôpital Saint Louis, Denis Diderot Paris 7 University, France
    Clin Microbiol Infect 18:E185-7. 2012
    ..Eleven (46%) patients died during follow up. After multivariate analysis, independent factors associated with death were the duration of neutropenia (p 0.022) and relapsing haematological malignancy (p 0.015)...
  36. doi Prevalence and clinical predictors of pulmonary tuberculosis among isolated inpatients: a prospective study
    M Lagrange-Xelot
    Department of Infectious Diseases, Laboratory of Microbiology, Saint Louis Hospital, AP HP and University of Paris Diderot Paris, Paris, France
    Clin Microbiol Infect 17:610-4. 2011
    ..8%) unnecessary isolations. In conclusion, the prevalence of PTB among isolated inpatients was high, and the use of a clinical decision rule in addition to clinical impression might improve isolation decisions...
  37. ncbi Fumagillin for treatment of intestinal microsporidiosis in renal transplant recipients
    L Champion
    Department of Renal Transplantation, Saint Louis Hospital and Paris Diderot Paris 7 University, Paris, France
    Am J Transplant 10:1925-30. 2010
    ..Intestinal microsporidiosis can cause subacute diarrhea in RT recipients. Fumagillin is an effective treatment with an acceptable safety profile, but monitoring of tacrolimus levels is warranted...
  38. ncbi The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
    F Raffi
    Department of Infectious Diseases, University Hospital Nantes, France
    Antivir Ther 5:267-72. 2000
    ..Combination therapy with the three reverse transcriptase (RT) inhibitors stavudine, once-daily didanosine and either once- or twice-daily nevirapine could be considered as an alternative option for first-line antiretroviral therapy...
  39. ncbi Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, AP HP, Paris University of Paris Diderot, Paris 7, France
    Lancet 372:646-55. 2008
    ..We compared these two combinations directly in treatment-naive patients...
  40. doi Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination
    A L Munier
    Infectious Diseases Department, St Louis Hospital, Assistance Publique Hopitaux de Paris APHP, 1, avenue Claude Vellefaux, 75010, Paris, France
    Infection 41:663-8. 2013
    ..Our aim was to assess the antibiotic susceptibilities and serotypes of strains responsible for IPD in HIV-infected patients...
  41. doi [Pneumocystis jirovecii pneumonia in HIV-infected patients]
    N De Castro
    Service de Maladies Infectieuses et Tropicales, Hopital Saint Louis, AP HP, 75010 Paris, France
    Rev Mal Respir 29:793-802. 2012
    ..Despite the dramatic decrease in opportunistic infections after the introduction of highly active antiretroviral therapy, Pneumocystis jirovecii pneumonia remains the major AIDS related infection in France...
  42. doi Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
    C Delaugerre
    Virology Department, Saint Louis Hospital APHP, INSERM U941 Paris 7 Diderot University, Paris, France
    HIV Med 13:517-25. 2012
    ..We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens...
  43. doi Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients
    A Alanio
    Laboratory of Parasitology Mycology, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris and Université Paris Diderot, Paris, France
    Clin Microbiol Infect 17:1531-7. 2011
    ..This is particularly relevant for patient management, especially in non-human immunodeficiency virus (HIV)-infected immunocompromised patients, who often present low-burden P. jirovecii infections that are not diagnosed microscopically...
  44. doi Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  45. doi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  46. doi Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)
    Sebastien Gallien
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 66:184-91. 2011
    ..once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine...
  47. pmc Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  48. doi Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
    S Grabar
    Department of Public Health, Cochin Hospital, Paris, France
    HIV Med 9:246-56. 2008
    ....
  49. doi Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
    AIDS 22:1203-11. 2008
    ..To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer...
  50. ncbi [Pneumocystis jiroveci pneumonia in patients with cancer: is it unavoidable?]
    N De Castro
    Service de Maladies Infectieuses et Tropicales, AP HP, Hopital Saint Louis, Paris, France
    Rev Mal Respir 24:741-50. 2007
    ..Although the use of prophylactic medication has reduced the incidence of Pneumocystis jiroveci pneumonia (PCP), it still occurs in cancer patients and is associated with a high morbidity and mortality...
  51. doi Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case–control study
    N De Castro
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, University of Paris Diderot, Paris, France
    Clin Microbiol Infect 16:1375-7. 2010
    ..66, p 0.017) remained significantly associated with PCP. In patients with a history of graft rejection, PCP prophylaxis should be maintained, especially among those with lymphocytopenia...
  52. ncbi A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients
    E Boulanger
    Department of Clinical Immunohematology, , Paris, France
    Hematol J 2:172-9. 2001
    ....
  53. ncbi Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials
    J M Molina
    Department of Infectious Diseases, Saint Louis Hospital APHP, INSERM U941 and University of Paris Diderot, Paris, France
    HIV Med 15:57-62. 2014
    ..These 96-week, ECHO/THRIVE pooled analyses evaluated data for antiretroviral treatment-naïve, HIV-1-infected adults with viral load (VL) ≤ 100 000 HIV-1 RNA copies/mL receiving rilpivirine or efavirenz...
  54. ncbi [Systemic lupus erythematosus and Kikuchi-Fujimoto disease mimicking tuberculosis]
    S Gallien
    Service de Maladies Infectieuses et Tropicales, Hopital Saint Louis, 1, avenue Claude de Vellefaux, 75010 Paris, France
    Med Mal Infect 38:392-5. 2008
    ..Atypical pseudo-infectious appearance of an inflammatory systemic disease is a rare occurrence and the diagnosis can be difficult...
  55. doi Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases
    S Gallien
    Infectious Disease Dept, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, University of Paris 7, 1, avenue Claude Vellefaux, Paris Cedex 10, 75475, France
    Infection 36:533-8. 2008
    ..Invasive aspergillosis (IA) is one of the most frequent, feared and life-threatening opportunistic infection in immunocompromised patients. We wished to assess the therapeutic outcome and identify prognostic factors of IA...
  56. ncbi Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus
    F Bani-Sadr
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris, France
    Clin Infect Dis 39:1062-4. 2004
    ..The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection...
  57. doi Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, France
    J Infect Dis 200:206-15. 2009
    ..Interleukin (IL)-2 increases CD4 T cell counts when combined with antiretroviral therapy (ART). Whether IL-2 alone can increase CD4 cell counts is unknown...
  58. ncbi Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study
    N De Castro
    Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Bone Marrow Transplant 36:879-83. 2005
    ..Long-term PCP prophylaxis should be maintained in patients receiving immunosuppressive drugs, and in those with low CD4+ T cell counts or a relapse of their hematological malignancy...
  59. ncbi [Metastatic cancer of the prostate in a young 40 year-old HIV-infected male patient]
    A Furco
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
    Presse Med 32:930-1. 2003
    ..Cancer of the prostate in HIV-infected patients has rarely been reported in the literature...
  60. ncbi [Adverse effects of antiretroviral treatments]
    M Lagrange-Xelot
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Paris
    Presse Med 34:1571-8. 2005
    ..They are one of the major disadvantages of combined treatments...
  61. doi [Follow-up with the assistance of TB-info software of 208 tuberculosis patients who were treated in 2004]
    A Bourgarit
    Hopital Saint Louis, Paris, France
    Rev Med Interne 30:841-6. 2009
    ..The impact of the TB-info software was assessed on the care of patients treated with antituberculosis regimen (ATT)...
  62. doi HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  63. ncbi [New strategies for antiretroviral treatment in HIV infected patients]
    V Garrait
    Clinique des Maladies Infectieuses et Tropicales, , 1 avenue Claude Vellefaux, 75010 Paris, France
    Pathol Biol (Paris) 49:67-71. 2001
    ..To ameliorate efficacy of the antiretroviral treatment and to avoid viral resistance, the tolerance and the ability to adhere are an important challenge...
  64. ncbi [Traceability of a resorbable implant for lipoatrophy: why should it be traced and how should this be done? Example of polylactic acid (Newfill)]
    C Dupont
    Service de Pharmacie, Hopital Saint Louis, APHP, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Med Mal Infect 37:824-7. 2007
    ..127 patients were included. The rate of traceability was 100%. Such traceability is therefore feasible and will have to be implemented for the follow-up of patients treated with future filling products...
  65. ncbi [Infection of a pneumonectomy site 16 years after intervention]
    L Hocqueloux
    Clinique des Maladies Infectieuses, Hopital Saint Louis, 1, avenue Claude Vellefaux, F 75010 Paris
    Presse Med 30:897-9. 2001
    ..Infection of the residual cavity after pneumonectomy generally occurs early after surgery...
  66. ncbi Venous access port--related bacteremia in patients with acquired immunodeficiency syndrome or cancer: the reservoir as a diagnostic and therapeutic tool
    P Longuet
    Department of Infectious and Tropical Diseases, Bichat-Claude Bernard Hospital, Paris, France
    Clin Infect Dis 32:1776-83. 2001
    ..Limited efficacy of the ALT might be explained by the presence of deposits of fibrin that include clusters of bacteria inside the reservoir of the port...
  67. doi Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides
    D Wendum
    APHP, Hopital St Antoine, Service d Anatomie Pathologique, Paris, France
    J Clin Pathol 62:361-3. 2009
    ..The METAVIR score, which is the most widely used score in France, was specifically elaborated and evaluated in chronic hepatitis C and has never been validated in HIV-hepatitis virus B (HBV) co-infected patients...
  68. ncbi African histoplasmosis infection with peritoneal involvement
    J B Arlet
    Service des Maladies Infectieuses et Tropicales, 1 avenue Claude Vellefaux, 75475 Paris 10, France
    Eur J Clin Microbiol Infect Dis 23:342-4. 2004
  69. ncbi Detection of Microsporidia, cryptosporidia and Giardia in swimming pools: a one-year prospective study
    Sandra Fournier
    Division of Infectious Diseases, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010, Paris, France
    FEMS Immunol Med Microbiol 33:209-13. 2002
    ..This study shows a low level of swimming pool water contamination by microsporidia, cryptosporidia or giardia, demonstrating the efficacy of cleaning filtration and disinfection procedures used in French swimming pools...
  70. ncbi Cerebral and spinal cord involvement resulting from invasive aspergillosis
    A Guermazi
    Department of Radiology, Saint Louis Hospital, AP HP, 1 avenue Claude Vellefaux, 75010 Paris, France
    Eur Radiol 12:147-50. 2002
    ..In this report we present and illustrate detailed imaging findings of central nervous system invasion by Aspergillus fumigatus in a 30-year-old woman, with emphasis on the spinal cord involvement...
  71. ncbi Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia
    S Fournier
    Department of Infectious Diseases, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    Eur J Clin Microbiol Infect Dis 21:892-6. 2002
    ..Despite treatment with antifungal agents (amphotericin B, fluconazole), 78% of patients died. Voriconazole may represent a promising therapy for this life-threatening infection...